Is precision medicine relevant in the age of COVID-19?

Zhou, Amy; Sabatello, Maya; Eyal, Gil; Lee, Sandra Soo‐Jin; Stiles, Deborah F.; Swanson, Ashley; Appelbaum, Paul S.

doi:10.1038/s41436-020-01088-4

Cited by 24 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other aspect to mention is that ELISA and CLIA are able to detect a single protein at once. Nevertheless micro-FTIR has multiplexing advantage enabling comparison of several metabolites which increases the quality of prognosis being a suitable tool for precision medicine [52]. Oour method enable in principle probe 500 samples by row while ELISA and CLIA usually are limited to 96 samples.…”

Section: Micro-ftir Reflectance Compared To Other Methodsmentioning

confidence: 99%

Micro-Fourier-Transform Infrared Reflectance Spectroscopy as Tool for Probing IgG Glycosylation in COVID-19 Patients

Bandeira

Madureira

Rossi

et al. 2021

Preprint

View full text Add to dashboard Cite

It has been reported that patients diagnosed with COVID-19 become critically ill primarily around the time of activation of the adaptive immune response. However the role of antibodies in the worsening of disease is not obvious. Higher titers of anti-spike immunoglobulin IgG1 associated to low fucosylation of the antibody Fc tail have been associated to excessive inflammatory response. In contrast it has been also reported in literature that NP-, S-, RBD- specific IgA, IgG, IgM are not associated with SARS-CoV-2 viral load, indicating that there is no obvious correlation between antibody response and viral antigen detection. In the present work the micro-Fourier-Transform Infrared reflectance spectroscopy (micro-FTIR) was employed to investigate blood serum samples of healthy and COVID-19 (mild or oligosynthomatic) individuals (82 healthcare workers volunteers in “Instituto de Infectologia Emilio Ribas”, São Paulo, Brazil). The molecular-level-sensitive, multiplexing quantitative and qualitative FTIR data probed on 1 mL of dryed biofluidwas compared to Signal-to-Cutoff index of chemiluminescent immunoassays CLIA and ELISA (IgG antibodies against SARS-CoV-2). Our main result indicated that 1702-1785 cm-1 spectral window (carbonyl C=O vibration) appeared to be a spectral marker of the degree of IgG glycosylation, allowing to probe distinctive subpopulations of COVID-19 patients, depending on their degree of severity. The specificity was 87.5 % while the detection rate of true positive was 100%. The computed area under the receiver operating curve was equivalent to CLIA, ELISA and other ATR-FTIR methods (> 0.85). In summary, overall discrimination of healthy and COVID-19 individuals and severity prediction as well could also be potentially implemented using micro-FTIR reflectance spectroscopy on blood serum samples. Considering the minimal and reagent-free sample preparation procedures combined to fast (few minutes) outcome of FTIR we can state that this technology is very suitable for fast screening of immune response of individuals with COVID-19. It would be an important tool in prospective studies, helping investigate the physiology of the asymptomatic, oligosymptomatic, or severe individuals and measure the extension of infection dissemination in patients.

show abstract

Section: Micro-ftir Reflectance Compared To Other Methodsmentioning

confidence: 99%

Micro-Fourier-Transform Infrared Reflectance Spectroscopy as Tool for Probing IgG Glycosylation in COVID-19 Patients

Bandeira

Madureira

Rossi

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has given rise to novel elements for the study of cultural implications of agendas of ST&I in contemporary healthcare. During the COVID-19 pandemic, societies have demonstrated great fragility in translating science and technology infrastructures into more efficient public health solutions to mitigate the disease around the world [ 8 ]. It revealed strong asymmetries in the global platforms of biomedical and health knowledge, as well as an inefficient system of governance and communication between approaches of ST&I and public health.…”

Section: Standi In Healthcare During the Covid-19 Pandemicmentioning

confidence: 99%

Rethinking approaches of science, technology, and innovation in healthcare during the COVID-19 pandemic: the challenge of translating knowledge infrastructures to public needs

Silva

Chammas

Novaes

2021

Health Res Policy Sys

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) outbreak made it clear that despite the potential of science, technology, and innovation (ST&I) to positively impact healthcare systems worldwide, as shown by the rapid development of SARS-CoV-2 test diagnostics and new mRNA vaccines, healthcare stakeholders have faced significant challenges in responding to the crisis through well-integrated ST&I-oriented health initiatives and policies. Therefore, the pandemic has mobilized experts, industry, and governments to evaluate alternative trajectories to promote a more efficient dialogue between ST&I and public health. This article presents a critical thinking about the contemporary asymmetries in the technical and political infrastructures available for particular approaches in ST&I in health, such as precision medicine, and for public health systems worldwide, uncovering a persistent gap in the translation of knowledge and technologies to adequately coordinated responses to the pandemic. We stimulate the understanding of this process as a matter of translation between platforms of knowledge and policy rationales shaped by different institutionalized frames of organizational practices and agendas. We draw attention to the need to strengthen governance tools for the promotion of ST&I as a strategic component of the post-pandemic agenda in public health, to prepare societies to respond efficiently to future emergencies.

show abstract

“…Personalized medicine is not a new approach, health workers and doctors have been relying on personalized medicine to cure cancer for the past few decades. Similarly, the use of personalized therapy is also being suggested in the time of COVID-19 [ 69 , 70 ]. As there is heterogeneity in the host response to SARS-CoV-2, a more precise and tailored treatment is required for favorable outcomes.…”

Section: Personalized Therapy For Covid-19 Mitigation?mentioning

confidence: 99%

Personalized Therapy: Can it Tame the COVID-19 Monster?

Arish

Naz

2021

Per. Med.

View full text Add to dashboard Cite

SARS-CoV-2, a recently emerged zoonotic virus, has resulted in unstoppable high morbidity and mortality rates worldwide. However, due to a limited knowledge of the dynamics of the SARS-CoV-2 infection, it has been observed that the current COVID-2019 therapy has led to some clinical repercussions. We discuss the adverse effects of drugs for COVID-2019 primarily based on some clinical trials. As therapeutic efficacy and toxicity of therapy may vary due to different, genetic determinants, sex, age and the ethnic background of test subjects, hence biomarker-based personalized therapy could be more appropriate. We will share our thoughts on the current landscape of personalized therapy as a roadmap to fight against SARS-CoV-2 or another emerging pathogen.

show abstract

Is precision medicine relevant in the age of COVID-19?

Cited by 24 publications

References 9 publications

Micro-Fourier-Transform Infrared Reflectance Spectroscopy as Tool for Probing IgG Glycosylation in COVID-19 Patients

Micro-Fourier-Transform Infrared Reflectance Spectroscopy as Tool for Probing IgG Glycosylation in COVID-19 Patients

Rethinking approaches of science, technology, and innovation in healthcare during the COVID-19 pandemic: the challenge of translating knowledge infrastructures to public needs

Personalized Therapy: Can it Tame the COVID-19 Monster?

Contact Info

Product

Resources

About